Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | PEPD | P12955 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | TPI1 | P60174 | 1/20 | 0.32 |
| ▸ | PGK1 | P00558 | 1/20 | 0.31 |
| ▸ | PGK2 | P07205 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL285627 | 0.97 | CA4 (0.48) | CA4PEPDTSHRFDPSBLM | |
| SCHEMBL27473070 | 0.94 | CA4 (0.46) | CA4PEPDTSHRFDPSBLM | |
| SCHEMBL28316038 | 0.90 | LMNA (0.43) | CA4PEPDTSHRBLMTDP1 | |
| SCHEMBL8561065 | 0.87 | LMNA (0.45) | CA4PEPDTSHRBLMTDP1 | |
| Phosphonic Acid SCHEMBL7991199 | 0.87 | CA4 (0.40) | CA4PEPDTSHRFDPSBLM | |
| SCHEMBL2201756 | 0.86 | TSHR (0.43) | CA4PEPDTSHRFDPSBLM | |
| SCHEMBL1685045 | 0.85 | ALDH1A1 (0.48) | CA4PEPDTSHR | |
| Ammonia Solution, Strong SCHEMBL1408904 | 0.83 | CA4 (0.42) | CA4PEPDTSHR | |
| SCHEMBL28732280 | 0.83 | CA4 (0.42) | CA4PEPDFDPSBLMTDP1 | |
| SCHEMBL27725186 | 0.83 | CA4 (0.42) | CA4PEPDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098347-A1 | PHOSPHOROUS BINDER FOR TREATMENT OF KIDNEY DISEASE | BIOLINK LIFE SCIENCES, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| US-7862836-B2 | Phosphorus binder for treatment of kidney disease | BIOLINK LIFE SCIENCES, INC. (US) | 2011-01-04 | — | — | US | disclosed |
| US-20060228424-A1 | Phosphorus binder for treatment of kidney disease | BIOLINK LIFE SCIENCES, INC. | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060228424-A1 | Phosphorus binder for treatment of kidney disease | ALPI, PHPT1, ATP6V1B1 | CA4 435/4885PEPD 274/4885TSHR 3535/4885 |
| US-20110098347-A1 | PHOSPHOROUS BINDER FOR TREATMENT OF KIDNEY DISEASE | ALPI, PHPT1, FABP2 | CA4 430/4885PEPD 218/4885TSHR 3444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.